Taysha Gene Therapies (TSHA) Held by Superinvestors
TAYSHA GENE THERAPIES INC (TSHA) is currently held by 1 superinvestors tracked by InsiderSet, with a combined reported market value of approximately $3.33M based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026.
Polen Capital Management is currently the largest disclosed institutional shareholder of TSHA tracked by InsiderSet, reporting ownership valued at approximately $3.33M in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $2.02M, representing an estimated loss of -39.35% since the filing period.
The top 10 institutional shareholders tracked on this page collectively account for approximately 100% of the total disclosed TSHA value among the investors covered in this analysis. Major shareholders include Polen Capital Management, and several other long-term asset managers with concentrated positions in TAYSHA GENE THERAPIES INC (TSHA).
This page ranks the largest institutional TSHA shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.
| Name | Investor/Manager | Portfolio % | Quantity | Reported Balance | Current Estimated Value | Gain/loss Since Filing | Estimated Portfolio Performance |
|---|---|---|---|---|---|---|---|
| Polen Capital Management | David M. Polen | 0.03% | 489,219 | $3,331,581 | $2,020,474 | -$1,311,107 | -39.35% |
Frequently asked questions about TSHA
Who are the largest superinvestors holding TSHA?
The largest superinvestors holding TSHA in the latest SEC Form 13F filings include Polen Capital Management. InsiderSet ranks these superinvestors by their latest reported TSHA position.
What does the TSHA superinvestors page include?
This page tracks TSHA positions reported by a curated group of notable institutional investors and fund managers through SEC Form 13F. TAYSHA GENE THERAPIES INC (TSHA) on this page reflects disclosed 13F holdings among those superinvestors, not every institutional shareholder of the stock.
How many superinvestors hold TSHA?
InsiderSet currently tracks 1 superinvestors reporting TSHA holdings in the latest available 13F data. This is the curated set on this page, not the total number of institutions that own TSHA.
How much TSHA stock do superinvestors hold?
Superinvestors tracked by InsiderSet disclosed approximately $3.33M in TSHA holdings for Q2 2026. This figure is reported 13F value as of the filing period, not necessarily today's market value, and it covers the curated superinvestors on this page rather than every institutional filer.
When were TSHA superinvestor holdings last updated?
The latest TSHA superinvestor holdings on InsiderSet are based on SEC Form 13F filings for the quarter ended June 30, 2026. Form 13F filings are generally reported after the quarter ends, so the holdings shown represent the latest publicly disclosed positions rather than real-time holdings.
Are superinvestor TSHA holdings real-time?
No. Form 13F data is not real-time. It represents positions reported by these superinvestors as of the end of the reporting quarter. A superinvestor may have changed its TSHA position after the reporting date.
Are superinvestors buying or selling TSHA?
Buying and selling can be analyzed by comparing TSHA positions across consecutive 13F reporting periods. InsiderSet's TSHA Ownership Changes page shows institutions that increased, reduced, initiated, or exited positions based on reported 13F holdings. View TSHA ownership changes.
How have superinvestor TSHA holdings changed over time?
InsiderSet tracks TSHA holdings among these superinvestors across multiple 13F reporting periods, so holder counts, reported value, and reported shares can be compared over time.